Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ridge Diagnostics, Inc. and Ameritox Ltd. Enter Into Licensing Agreement for Depression Biomarker Blood Test

Published: Tuesday, April 10, 2012
Last Updated: Tuesday, April 10, 2012
Bookmark and Share
Collaboration prepares MDDScore test commercialization for primary care and pain medicine physicians.

Assay analyzing multiple biomarkers could be valuable aid to diagnosis and treatment monitoring.

Ridge Diagnostics(TM), Inc. announced today it has entered into an exclusive agreement with Ameritox(SM), Ltd. for the license rights to its proprietary developmental blood test MDDScore(TM), a multiple biomarker analysis for Major Depressive Disorder (MDD) for primary care and pain physicians. As part of the agreement, Ameritox has agreed to make an undisclosed equity investment in Ridge and commit to a next-stage clinical development program.

Antidepressant drugs are among the most frequently prescribed medications in the U.S. today, where depression impacts some 19 million adults each year. A biological test for depression may aid physicians in the differential diagnosis of MDD, assist in the selection of proper patient treatment and improve healthcare cost management.

“Ameritox investment in Ridge will likely accelerate the MDDScore test development and advance access to millions of patients already under the care of primary-care and pain-management physicians,” said Lonna J. Williams, CEO of Ridge Diagnostics. “Ameritox longstanding investments in diagnostic science, and now in the Ridge technology, validate the importance of the MDDScore and demonstrate their commitment to improving patient well-being.”

The MDDScore test developed by Ridge Diagnostics measures ten biomarker levels associated with factors such as inflammation, development and maintenance of neurons and interaction between brain structures involved with stress response and other key biological functions. Measurements are analyzed to produce an MDDScore which may help physicians determine whether a patient has major depression.

A recent peer-reviewed study with 70 adults who had been diagnosed with major depression evaluated in a pilot and replication study using the MDDScore appears in Molecular Psychiatry (February 2012) and indicates the test diagnosed major depression with a high degree of accuracy within the study population. The study is co-authored by investigators from Massachusetts General Hospital, Boston, MA; Vanderbilt University, Nashville, TN; Cambridge Health Alliance, Boston, MA, and Elizabeth Medical Center, Brighton, MA.

“Biomarkers are an important emerging scientific tool to better understanding illness, and may enable health professionals to improve the accuracy of diagnosis and help match the right treatment to the right patient,” said Ancelmo Lopes, CEO, Ameritox Ltd. “Personalizing care offers the best use for precious healthcare resources. We are committed to providing physicians with tools to support their care decisions. We are excited to launch clinical trials to evaluate the utility of MDDScore in primary care and pain medicine settings."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Gene That Lowers Heart Attack Risk Identified
Individuals with a rare twelve-letter deletion from a gene on chromosome 17 have significantly reduced non-HDL cholesterol levels and a 35% lower than average risk of heart disease.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Transcription Factor Isoforms Implicated in Colon Diseases
UC Riverside study explains how distribution of two forms of a transcription factor in the colon influence risk of disease.
Roundup Impacts Gene Expression
Study published on the impact of low-dose toxicity of Roundup weed-killer on gene expression profiles.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Triple-Negative Breast Cancer Target Is Found
Researchers at UC Berkeley discover a target that drives cancer metabolism in triple-negative breast cancer.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!